BOONTON, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) today announced that it has entered into a financing agreement for $20 million three-year non-convertible, senior secured term notes and up to 1,500,000 shares of Common Stock. Unigene will draw down $15 million at closing and have an option for an additional $5 million within two years of the closing. An entity managed by Victory Park Capital Advisors, LLC is the sole investor in the transaction. Details of the transaction can be found in the Company’s 8-K which will be filed with the SEC.
